Nifty
Sensex
:
:
23851.65
78553.20
414.45 (1.77%)
1508.91 (1.96%)

Pharmaceuticals & Drugs - API

Rating :
N/A

BSE: 532815 | NSE: SMSPHARMA

216.16
06-Feb-2025
  • Open
  • High
  • Low
  • Previous Close
  •  211.95
  •  221.79
  •  211.00
  •  212.06
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  137663
  •  298.41
  •  398.00
  •  175.25

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 1,920.20
  • 29.05
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 2,196.31
  • 0.18%
  • 3.10

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 66.26%
  • 1.60%
  • 26.35%
  • FII
  • DII
  • Others
  • 0.08%
  • 2.43%
  • 3.28%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 1.92
  • 11.48
  • 10.91

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.09
  • 7.85
  • 0.37

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.44
  • 8.52
  • -10.17

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 18.18
  • 24.23
  • 30.31

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.27
  • 2.52
  • 2.55

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 11.72
  • 14.24
  • 17.01

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Net Sales
173.35
161.48
7.35%
196.75
166.64
18.07%
164.45
135.34
21.51%
245.80
149.43
64.49%
Expenses
140.14
132.48
5.78%
165.28
138.82
19.06%
130.94
109.16
19.95%
212.18
126.19
68.14%
EBITDA
33.21
29.00
14.52%
31.47
27.82
13.12%
33.51
26.18
28.00%
33.62
23.24
44.66%
EBIDTM
19.16%
17.96%
15.99%
16.70%
20.38%
19.35%
13.68%
15.55%
Other Income
2.13
1.49
42.95%
1.31
0.81
61.73%
1.37
0.51
168.63%
1.65
1.26
30.95%
Interest
4.20
5.95
-29.41%
4.61
5.57
-17.24%
4.67
6.32
-26.11%
5.61
5.88
-4.59%
Depreciation
8.70
8.01
8.61%
8.62
7.90
9.11%
8.38
7.69
8.97%
7.92
7.97
-0.63%
PBT
22.44
16.53
35.75%
19.54
15.16
28.89%
21.83
12.68
72.16%
21.74
10.63
104.52%
Tax
5.36
4.24
26.42%
5.68
3.11
82.64%
5.46
3.87
41.09%
5.69
2.57
121.40%
PAT
17.08
12.29
38.97%
13.86
12.05
15.02%
16.37
8.81
85.81%
16.05
8.07
98.88%
PATM
9.85%
7.61%
7.05%
7.23%
9.96%
6.51%
6.53%
5.40%
EPS
2.15
1.36
58.09%
1.67
1.39
20.14%
1.95
1.10
77.27%
2.04
0.73
179.45%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 07
Net Sales
780.35
709.26
522.05
519.87
563.18
411.95
464.91
464.93
445.49
611.53
199.84
Net Sales Growth
27.32%
35.86%
0.42%
-7.69%
36.71%
-11.39%
0.00%
4.36%
-27.15%
206.01%
 
Cost Of Goods Sold
449.84
424.26
335.80
275.45
340.00
246.36
292.71
289.90
295.85
385.15
109.95
Gross Profit
330.51
285.00
186.24
244.43
223.18
165.59
172.20
175.03
149.64
226.38
89.88
GP Margin
42.35%
40.18%
35.67%
47.02%
39.63%
40.20%
37.04%
37.65%
33.59%
37.02%
44.98%
Total Expenditure
648.54
592.50
467.52
405.26
442.04
331.92
374.77
371.59
370.35
522.32
150.38
Power & Fuel Cost
-
47.12
35.97
32.58
23.31
18.99
21.75
22.57
18.23
33.81
8.95
% Of Sales
-
6.64%
6.89%
6.27%
4.14%
4.61%
4.68%
4.85%
4.09%
5.53%
4.48%
Employee Cost
-
56.78
50.08
51.02
41.17
39.35
35.59
32.80
26.92
38.11
5.81
% Of Sales
-
8.01%
9.59%
9.81%
7.31%
9.55%
7.66%
7.05%
6.04%
6.23%
2.91%
Manufacturing Exp.
-
37.87
28.08
25.80
16.28
14.89
13.29
12.14
10.35
37.94
7.31
% Of Sales
-
5.34%
5.38%
4.96%
2.89%
3.61%
2.86%
2.61%
2.32%
6.20%
3.66%
General & Admin Exp.
-
20.68
12.48
15.32
14.93
8.05
8.69
8.45
9.00
10.51
3.36
% Of Sales
-
2.92%
2.39%
2.95%
2.65%
1.95%
1.87%
1.82%
2.02%
1.72%
1.68%
Selling & Distn. Exp.
-
4.73
3.82
3.42
5.09
3.70
2.25
4.81
9.67
15.99
10.41
% Of Sales
-
0.67%
0.73%
0.66%
0.90%
0.90%
0.48%
1.03%
2.17%
2.61%
5.21%
Miscellaneous Exp.
-
1.07
1.27
1.67
1.25
0.58
0.49
0.91
0.33
0.80
10.41
% Of Sales
-
0.15%
0.24%
0.32%
0.22%
0.14%
0.11%
0.20%
0.07%
0.13%
2.30%
EBITDA
131.81
116.76
54.53
114.61
121.14
80.03
90.14
93.34
75.14
89.21
49.46
EBITDA Margin
16.89%
16.46%
10.45%
22.05%
21.51%
19.43%
19.39%
20.08%
16.87%
14.59%
24.75%
Other Income
6.46
4.46
4.91
5.20
3.45
5.11
3.40
2.39
1.45
3.61
3.03
Interest
19.09
23.60
21.97
19.16
11.19
12.32
11.92
15.48
15.82
17.11
8.23
Depreciation
33.62
31.52
32.13
32.15
22.28
22.07
19.27
19.90
19.18
19.43
4.58
PBT
85.55
66.11
5.35
68.50
91.12
50.76
62.35
60.35
41.58
56.27
39.67
Tax
22.19
16.91
1.47
0.62
30.16
18.07
20.90
19.89
5.97
14.63
14.20
Tax Rate
25.94%
25.58%
27.48%
0.91%
33.10%
35.60%
33.52%
32.96%
14.36%
26.00%
35.80%
PAT
63.36
49.20
3.88
67.88
60.96
32.69
41.45
40.45
35.61
41.64
25.47
PAT before Minority Interest
63.36
49.20
3.88
67.88
60.96
32.69
41.45
40.45
35.61
41.64
25.47
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
8.12%
6.94%
0.74%
13.06%
10.82%
7.94%
8.92%
8.70%
7.99%
6.81%
12.75%
PAT Growth
53.71%
1,168.04%
-94.28%
11.35%
86.48%
-21.13%
2.47%
13.59%
-14.48%
63.49%
 
EPS
7.14
5.55
0.44
7.65
6.87
3.69
4.67
4.56
4.01
4.69
2.87

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 07
Shareholder's Funds
536.33
460.53
470.29
410.53
348.24
321.92
284.49
254.74
293.60
192.08
Share Capital
8.47
8.47
8.47
8.47
8.47
8.47
8.47
8.47
8.47
10.00
Total Reserves
499.29
452.06
461.82
402.06
339.77
313.45
276.02
246.28
285.14
182.07
Non-Current Liabilities
166.05
164.17
192.73
206.26
114.47
94.35
96.58
91.41
161.56
88.21
Secured Loans
120.89
119.93
148.30
146.21
67.02
61.01
70.20
73.02
109.58
65.92
Unsecured Loans
1.20
1.20
1.20
1.20
1.20
1.20
1.20
1.20
3.64
6.95
Long Term Provisions
1.16
1.40
1.57
1.84
1.73
1.52
2.18
1.35
3.43
0.00
Current Liabilities
346.72
254.97
211.48
211.43
154.21
156.05
134.29
156.00
200.43
49.03
Trade Payables
151.32
107.43
72.86
65.44
44.49
47.70
39.27
66.75
84.40
23.86
Other Current Liabilities
65.37
52.65
54.69
58.31
38.84
23.32
22.91
19.95
40.37
0.33
Short Term Borrowings
114.00
93.79
67.91
70.86
61.16
70.81
58.40
59.76
72.75
0.00
Short Term Provisions
16.03
1.10
16.02
16.82
9.72
14.22
13.71
9.54
2.90
24.84
Total Liabilities
1,049.10
879.67
874.50
828.22
616.92
572.32
515.36
502.15
655.59
329.32
Net Block
437.26
412.02
437.99
457.36
280.49
281.26
279.26
290.45
370.35
68.84
Gross Block
631.84
575.55
569.62
558.80
360.77
339.57
318.34
309.63
500.81
96.16
Accumulated Depreciation
194.58
163.53
131.63
101.44
80.29
58.31
39.08
19.18
130.46
27.32
Non Current Assets
500.20
468.96
482.45
502.88
389.13
351.22
334.04
335.80
408.04
83.85
Capital Work in Progress
30.27
33.19
11.00
6.74
42.12
18.30
8.20
7.76
12.80
15.02
Non Current Investment
10.94
10.52
21.53
27.30
25.81
26.99
28.38
29.10
20.51
0.00
Long Term Loans & Adv.
19.04
10.70
9.32
9.10
38.47
22.55
16.19
6.58
4.37
0.00
Other Non Current Assets
2.69
2.54
2.61
2.38
2.25
2.13
2.01
1.90
0.00
0.00
Current Assets
548.89
410.70
392.05
325.33
227.78
221.09
181.32
166.36
247.55
233.89
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.03
Inventories
233.70
223.50
251.10
137.79
129.20
136.40
107.48
92.52
112.68
49.57
Sundry Debtors
236.23
148.35
48.52
105.68
48.77
26.02
24.15
21.32
61.09
59.98
Cash & Bank
36.20
7.47
46.66
40.51
9.65
14.88
12.71
12.37
15.08
95.71
Other Current Assets
42.76
6.00
6.39
19.18
40.16
43.79
36.98
40.15
58.70
28.60
Short Term Loans & Adv.
35.99
25.39
39.39
22.17
19.20
17.06
14.89
11.67
23.49
26.79
Net Current Assets
202.18
155.74
180.57
113.90
73.57
65.04
47.03
10.36
47.13
184.86
Total Assets
1,049.09
879.66
874.50
828.21
616.91
572.31
515.36
502.16
655.59
329.31

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 07
Cash From Operating Activity
50.12
22.45
45.06
90.45
39.71
49.76
31.81
73.47
61.22
14.33
PBT
66.11
5.35
68.50
91.12
50.76
62.35
60.35
41.58
56.27
39.67
Adjustment
53.97
52.99
49.86
27.76
28.66
26.81
31.08
31.58
28.14
18.09
Changes in Working Capital
-54.55
-31.29
-58.38
-12.38
-27.60
-26.02
-48.48
9.40
-1.17
-29.61
Cash after chg. in Working capital
65.52
27.05
59.98
106.50
51.82
63.14
42.95
82.56
83.24
28.16
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-15.40
-4.60
-14.92
-16.05
-12.10
-13.38
-11.14
-9.09
-22.02
-5.60
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-52.07
-29.76
-27.15
-151.59
-42.56
-34.67
-16.58
-38.96
-96.72
-31.70
Net Fixed Assets
-53.37
-28.12
-15.08
-162.65
-45.02
-31.33
-9.15
128.49
-346.44
Net Investments
0.00
-0.10
0.00
0.00
0.00
0.00
-8.02
-15.71
-17.94
Others
1.30
-1.54
-12.07
11.06
2.46
-3.34
0.59
-151.74
267.66
Cash from Financing Activity
30.68
-31.97
-11.75
92.02
-2.40
-12.92
-14.89
-33.19
44.34
106.55
Net Cash Inflow / Outflow
28.73
-39.27
6.16
30.88
-5.25
2.17
0.35
1.32
8.84
89.18
Opening Cash & Equivalents
7.31
46.58
40.42
9.54
14.80
12.63
12.29
11.25
2.41
6.53
Closing Cash & Equivalent
36.04
7.31
46.58
40.42
9.54
14.80
12.63
12.29
11.25
95.71

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 07
Book Value (Rs.)
59.98
54.40
55.56
48.50
41.14
38.03
33.61
30.09
34.68
18.05
ROA
5.10%
0.44%
7.97%
8.44%
5.50%
7.62%
7.95%
6.15%
8.46%
7.73%
ROE
10.16%
0.83%
15.41%
16.07%
9.76%
13.67%
15.00%
12.99%
17.57%
14.11%
ROCE
11.73%
3.79%
12.60%
17.62%
13.06%
16.57%
18.17%
12.73%
19.54%
18.91%
Fixed Asset Turnover
1.24
0.97
0.98
1.32
1.29
1.53
1.59
1.12
2.11
2.24
Receivable days
93.46
65.01
50.80
46.40
30.27
18.23
16.66
33.12
35.09
101.66
Inventory Days
111.10
156.71
128.12
80.21
107.49
88.61
73.28
82.47
47.02
84.02
Payable days
111.30
97.98
91.63
59.01
46.62
40.24
46.81
71.90
36.96
57.46
Cash Conversion Cycle
93.25
123.74
87.30
67.61
91.14
66.60
43.12
43.69
45.14
128.22
Total Debt/Equity
0.55
0.55
0.55
0.61
0.44
0.45
0.51
0.59
0.70
0.40
Interest Cover
3.80
1.24
4.57
9.14
5.12
6.23
4.90
3.63
4.29
5.82

News Update:


  • SMS Pharmaceuticals completes USFDA inspection at Hyderabad facility
    22nd Mar 2025, 11:54 AM

    The inspection, conducted from March 17, 2025 to March 21, 2025, concluded with one observation in Form 483

    Read More
  • SMS Pharmaceuticals - Quarterly Results
    12th Feb 2025, 14:21 PM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.